Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
10.0
5.5
Journals
Pharmaceutics
Special Issues
Personalized Medicine in Clinical Pharmaceutics
share announcement

Personalized Medicine in Clinical Pharmaceutics

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Clinical Pharmaceutics".

Deadline for manuscript submissions: 20 March 2026 | Viewed by 939

Special Issue Editor

Prof. Dr. Sandy Jeong Rhie

E-Mail Website
Guest Editor
College of Pharmacy, Ewha Womans University, Seoul 03760, Republic of Korea
Interests: pharmacotherapy; precision medicine; outcome research

Special Issue Information

Dear Colleagues,

Pharmaceutics is pleased to announce a Special Issue entitled “Personalized Medicine in Clinical Pharmaceutics”. Personalized medicine is revolutionizing healthcare by enabling the tailoring of treatments to individual characteristics, such as health exposure, genetic profiles, disease phenotypes, and lifestyle factors. In clinical pharmaceutics and pharmaceutical care, this approach is driving advancements in drug formulation, delivery systems, and treatment applications to optimize efficacy while minimizing adverse effects. Technologies such as 3D printing, nanotechnology, pharmacogenomics-based drug selection, adaptive drug delivery systems, and AI-based applications are enabling the development of patient-specific dosage forms and individualized treatment regimens.

This Special Issue will focus on cutting-edge research in the design, development, and evaluation of personalized pharmaceutics, including precision formulations, target-specific drug delivery platforms, and real-time monitoring systems for individualized therapy.

We invite researchers, clinicians, and industry professionals to contribute original research and reviews on personalized pharmaceutical science and patient care optimization for improved patient outcomes. We look forward to receiving your contributions.

Prof. Dr. Sandy Jeong Rhie
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • personalized medicine
  • precision pharmaceutics
  • therapy optimization
  • pharmacogenomics
  • 3D printing
  • nanotechnology
  • targeted drug delivery
  • individualized therapy
  • patient-specific formulations
  • adaptive drug delivery
  • clinical pharmaceutics
  • pharmaceutical care

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

31 pages, 2031 KB  
Review
Breaking Barriers: Immune Checkpoint Inhibitors in Breast Cancer
by Bartosz Dmuchowski, Witold Wit Hryniewicz, Igor Barczak, Kacper Fręśko, Zuzanna Szarzyńska, Hubert Węclewski, Jan Kazimierz Ślężak, Paula Dobosz and Hanna Gryczka
Pharmaceutics 2026, 18(1), 34; https://doi.org/10.3390/pharmaceutics18010034 - 26 Dec 2025
Viewed by 757
Abstract
Breast cancer remains the most commonly diagnosed malignancy among women worldwide and continues to pose significant therapeutic challenges, particularly in advanced and refractory disease. Although traditionally considered less immunogenic compared with other solid tumours, growing evidence demonstrates that subsets of breast cancer, particularly [...] Read more.
Breast cancer remains the most commonly diagnosed malignancy among women worldwide and continues to pose significant therapeutic challenges, particularly in advanced and refractory disease. Although traditionally considered less immunogenic compared with other solid tumours, growing evidence demonstrates that subsets of breast cancer, particularly triple-negative and HER2-positive subtypes, exhibit immune-responsive features. This recognition has spurred the development and clinical evaluation of immunotherapeutic strategies, with immune checkpoint inhibitors (ICIs) emerging as the most prominent approach. This new class of drugs targeting the programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) axis has demonstrated meaningful clinical activity in select patient populations, leading to regulatory approvals in combination with chemotherapy for advanced triple-negative breast cancer. Despite these advances, response rates remain modest, and the benefits are largely restricted to patients with PD-L1-positive tumours. Ongoing studies are evaluating predictive biomarkers, optimal treatment combinations, and mechanisms of resistance to expand the efficacy of ICIs across broader breast cancer subtypes. Furthermore, novel checkpoint targets such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), lymphocyte-activation gene 3 (LAG-3), and T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains (TIGIT) are under investigation, with the potential to enhance or complement PD-1/PD-L1 blockade. This review summarises the current state of knowledge on breast cancer immunotherapy with an emphasis on ICIs, highlighting key clinical trial findings, as well as emerging biomarkers of response, and strategies to overcome therapeutic resistance, if cancer cells eventually develop resistance. By integrating preclinical insights with clinical progress, we aim to provide a comprehensive overview of the evolving role of checkpoint blockade in breast cancer and outline future directions to optimise patient outcomes. Full article
(This article belongs to the Special Issue Personalized Medicine in Clinical Pharmaceutics)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop